Literature DB >> 7742034

A general model for the surface glycoproteins of HIV and other retroviruses.

W R Gallaher1, J M Ball, R F Garry, A M Martin-Amedee, R C Montelaro.   

Abstract

A hypothetical model of the surface (SU) glycoproteins of human immunodeficiency virus (HIV) and other retroviruses is proposed. The model is based on repetition of a limited number of sequence motifs conserved within the virus family; similarities in biological, immunological, or genetic properties; as well as the tendency for regions of dissimilar sequence to share protein structures predicted by computer algorithms. It is proposed that the protein consists of three structural and functional domains interspersed by relatively conserved interdomain regions. For each retrovirus, these amino-terminal, central, and carboxy-terminal domains may play different roles in binding, postbinding events, and the immune response to viral infection.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7742034     DOI: 10.1089/aid.1995.11.191

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  31 in total

1.  Neutralizing human monoclonal antibodies to conformational epitopes of human T-cell lymphotropic virus type 1 and 2 gp46.

Authors:  K G Hadlock; J Rowe; S Perkins; P Bradshaw; G Y Song; C Cheng; J Yang; R Gascon; J Halmos; S M Rehman; M S McGrath; S K Foung
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

2.  Localization of the labile disulfide bond between SU and TM of the murine leukemia virus envelope protein complex to a highly conserved CWLC motif in SU that resembles the active-site sequence of thiol-disulfide exchange enzymes.

Authors:  A Pinter; R Kopelman; Z Li; S C Kayman; D A Sanders
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

3.  High-mannose-specific deglycosylation of HIV-1 gp120 induced by resistance to cyanovirin-N and the impact on antibody neutralization.

Authors:  Qinxue Hu; Naheed Mahmood; Robin J Shattock
Journal:  Virology       Date:  2007-07-23       Impact factor: 3.616

4.  A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure.

Authors:  J M Binley; R W Sanders; B Clas; N Schuelke; A Master; Y Guo; F Kajumo; D J Anselma; P J Maddon; W C Olson; J P Moore
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

5.  Mutational pathways, resistance profile, and side effects of cyanovirin relative to human immunodeficiency virus type 1 strains with N-glycan deletions in their gp120 envelopes.

Authors:  Jan Balzarini; Kristel Van Laethem; Willy J Peumans; Els J M Van Damme; Anders Bolmstedt; Federico Gago; Dominique Schols
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

6.  Activity and safety of synthetic lectins based on benzoboroxole-functionalized polymers for inhibition of HIV entry.

Authors:  Alamelu Mahalingam; Anthony R Geonnotti; Jan Balzarini; Patrick F Kiser
Journal:  Mol Pharm       Date:  2011-09-26       Impact factor: 4.939

7.  Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein.

Authors:  J P Moore; J Sodroski
Journal:  J Virol       Date:  1996-03       Impact factor: 5.103

8.  Betaretroviral envelope subunits are noncovalently associated and restricted to the mammalian class.

Authors:  Jamie E Henzy; John M Coffin
Journal:  J Virol       Date:  2012-12-05       Impact factor: 5.103

9.  Multivalent benzoboroxole functionalized polymers as gp120 glycan targeted microbicide entry inhibitors.

Authors:  Julie I Jay; Bonnie E Lai; David G Myszka; Alamelu Mahalingam; Kris Langheinrich; David F Katz; Patrick F Kiser
Journal:  Mol Pharm       Date:  2010-02-01       Impact factor: 4.939

10.  Folding, assembly, and intracellular trafficking of the human immunodeficiency virus type 1 envelope glycoprotein analyzed with monoclonal antibodies recognizing maturational intermediates.

Authors:  A Otteken; P L Earl; B Moss
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.